HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Identification of Rare Loss-of-Function Genetic Variation Regulating Body Fat Distribution.

AbstractCONTEXT:
Biological and translational insights from large-scale, array-based genetic studies of fat distribution, a key determinant of metabolic health, have been limited by the difficulty in linking predominantly noncoding variants to specific gene targets. Rare coding variant analyses provide greater confidence that a specific gene is involved, but do not necessarily indicate whether gain or loss of function (LoF) would be of most therapeutic benefit.
OBJECTIVE:
This work aimed to identify genes/proteins involved in determining fat distribution.
METHODS:
We combined the power of genome-wide analysis of array-based rare, nonsynonymous variants in 450 562 individuals in the UK Biobank with exome-sequence-based rare LoF gene burden testing in 184 246 individuals.
RESULTS:
The data indicate that the LoF of 4 genes (PLIN1 [LoF variants, P = 5.86 × 10-7], INSR [LoF variants, P = 6.21 × 10-7], ACVR1C [LoF + moderate impact variants, P = 1.68 × 10-7; moderate impact variants, P = 4.57 × 10-7], and PDE3B [LoF variants, P = 1.41 × 10-6]) is associated with a beneficial effect on body mass index-adjusted waist-to-hip ratio and increased gluteofemoral fat mass, whereas LoF of PLIN4 (LoF variants, P = 5.86 × 10-7 adversely affects these parameters. Phenotypic follow-up suggests that LoF of PLIN1, PDE3B, and ACVR1C favorably affects metabolic phenotypes (eg, triglycerides [TGs] and high-density lipoprotein [HDL] cholesterol concentrations) and reduces the risk of cardiovascular disease, whereas PLIN4 LoF has adverse health consequences. INSR LoF is associated with lower TG and HDL levels but may increase the risk of type 2 diabetes.
CONCLUSION:
This study robustly implicates these genes in the regulation of fat distribution, providing new and in some cases somewhat counterintuitive insight into the potential consequences of targeting these molecules therapeutically.
AuthorsMine Koprulu, Yajie Zhao, Eleanor Wheeler, Liang Dong, Nuno Rocha, Chen Li, John D Griffin, Satish Patel, Marcel Van de Streek, Craig A Glastonbury, Isobel D Stewart, Felix R Day, Jian'an Luan, Nicholas Bowker, Laura B L Wittemans, Nicola D Kerrison, Lina Cai, Debora M E Lucarelli, Inês Barroso, Mark I McCarthy, Robert A Scott, Vladimir Saudek, Kerrin S Small, Nicholas J Wareham, Robert K Semple, John R B Perry, Stephen O'Rahilly, Luca A Lotta, Claudia Langenberg, David B Savage
JournalThe Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 107 Issue 4 Pg. 1065-1077 (03 24 2022) ISSN: 1945-7197 [Electronic] United States
PMID34875679 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.
Chemical References
  • ACVR1C protein, human
  • Activin Receptors, Type I
Topics
  • Activin Receptors, Type I (genetics)
  • Body Fat Distribution
  • Diabetes Mellitus, Type 2 (genetics)
  • Exome
  • Genetic Variation
  • Genome-Wide Association Study
  • Humans

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: